Table 3.
Number of patients with a dose increase or decrease after the first 2 weeks of the extension phase grouped by double-blind medication: analgesia study
Treatment during double-blind phase | Decrease in dose, n (%) | Increase in dose, n (%) |
---|---|---|
Oxycodone PR/naloxone PR | ||
20 mg/10 mg | 0 (0) | 22 (37) |
40 mg/20 mg | 17 (24) | 19 (27) |
Oxycodone PR | ||
20 mg | 3 (5) | 24 (37) |
40 mg | 8 (15) | 18 (33) |
Placebo | ||
20 mg | 2 (3) | 33 (46) |
40 mg | 9 (17) | 20 (38) |
PR, prolonged release.